Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.15−0.10 (-1.08%)
Close on Nov 18, 2026Market cap $1.55BP/E –Yield –
Vir Biotechnology revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Vir Biotechnology's revenue for the twelve months ending Jun 30, 2026 was $303.23M, up 1495.9% year over year. For fiscal 2025 it was $68.56M, down 7.6% from the year before. The highest annual figure on record is $1.62B in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.56M | -7.6% |
| FY2024 | Dec 31, 2024 | $74.21M | -13.9% |
| FY2023 | Dec 31, 2023 | $86.18M | -94.7% |
| FY2022 | Dec 31, 2022 | $1.62B | +47.5% |
| FY2021 | Dec 31, 2021 | $1.10B | +1334.4% |
| FY2020 | Dec 31, 2020 | $76.37M | +843.9% |
| FY2019 | Dec 31, 2019 | $8.09M | -24.2% |
| FY2018 | Dec 31, 2018 | $10.67M | +293.9% |
| FY2017 | Dec 31, 2017 | $2.71M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $238.95M | +19582.5% |
| Q1 FY2026 | Mar 31, 2026 | -$29.00K | -101.0% |
| Q4 FY2025 | Dec 31, 2025 | $64.07M | +417.8% |
| Q3 FY2025 | Sep 30, 2025 | $240.00K | -89.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.21M | -60.5% |
| Q1 FY2025 | Mar 31, 2025 | $3.03M | -94.6% |
| Q4 FY2024 | Dec 31, 2024 | $12.37M | -26.3% |
| Q3 FY2024 | Sep 30, 2024 | $2.38M | -9.8% |
| Q2 FY2024 | Jun 30, 2024 | $3.08M | -19.0% |
| Q1 FY2024 | Mar 31, 2024 | $56.38M | -10.5% |
| Q4 FY2023 | Dec 31, 2023 | $16.79M | -66.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.64M | -99.3% |
| Q2 FY2023 | Jun 30, 2023 | $3.80M | – |
| Q1 FY2023 | Mar 31, 2023 | $62.96M | -94.9% |
| Q4 FY2022 | Dec 31, 2022 | $49.41M | -93.9% |
| Q3 FY2022 | Sep 30, 2022 | $374.56M | +261.5% |
| Q2 FY2022 | Jun 30, 2022 | -$40.63M | -122.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.23B | +62271.4% |
| Q4 FY2021 | Dec 31, 2021 | $812.75M | +46771.2% |
| Q3 FY2021 | Sep 30, 2021 | $103.62M | +5274.3% |
| Q2 FY2021 | Jun 30, 2021 | $177.07M | +164.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.98M | -65.4% |
| Q4 FY2020 | Dec 31, 2020 | $1.73M | +76.9% |
| Q3 FY2020 | Sep 30, 2020 | $1.93M | +37.4% |
| Q2 FY2020 | Jun 30, 2020 | $66.99M | +3172.5% |
| Q1 FY2020 | Mar 31, 2020 | $5.72M | +56.2% |
| Q4 FY2019 | Dec 31, 2019 | $980.00K | -68.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.40M | -51.4% |
| Q2 FY2019 | Jun 30, 2019 | $2.05M | -8.0% |
| Q1 FY2019 | Mar 31, 2019 | $3.66M | +50.5% |
| Q4 FY2018 | Dec 31, 2018 | $3.13M | – |
| Q3 FY2018 | Sep 30, 2018 | $2.89M | – |
| Q2 FY2018 | Jun 30, 2018 | $2.22M | – |
| Q1 FY2018 | Mar 31, 2018 | $2.43M | – |
See a number that looks wrong?